

Form Title Hip Fracture, Adult Pre-Op Order Set

Form Number 21170Bond

© 2018, Alberta Health Services, CKCM



This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not apply to content for which the Alberta Health Services is not the copyright owner.

To view a copy of this license, visit

https://creativecommons.org/licenses/by-nc-nd/4.0/

**Disclaimer:** This material is intended for use by clinicians only and is provided on an "as is", "where is" basis. Although reasonable efforts were made to confirm the accuracy of the information, Alberta Health Services does not make any representation or warranty, express, implied or statutory, as to the accuracy, reliability, completeness, applicability or fitness for a particular purpose of such information. This material is not a substitute for the advice of a qualified health professional. Alberta Health Services expressly disclaims all liability for the use of these materials, and for any claims, actions, demands or suits arising from such use.



Select orders by placing a (✓) in the associated box For more information, see *Fractured Hip Care Pathway* 

Last Name (Legal)		First Name (Legal)		
Preferred Name □ Last □ First			DOB <sub>0</sub>	(dd-Mon-yyyy)
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Mal ☐ Non-binary/Prefer not to disc			se (X)	☐ Female ☐ Unknown

### Goals of Care Designation

Conversations leading to the ordering of a Goals of Care Designation (GCD), should take place as early as possible in a patient's course of care.

The Goals of Care Designation is created, or the previous GCD is affirmed or changed resulting from this conversation with the patient or, where appropriate, the Alternate Decision-Maker.

Complete the Goals of Care Designation (GCD) Order Set within your electronic system, or if using paper process, complete Provincial Goals of Care Designation (GCD) paper form (form #103547)

☐ Clinical Communication: Place copy of Personal Directive on chart and determine if enacted
Admit, Transfer, Discharge
<ul> <li>☑ Anticipated Date of Discharge:</li> <li>☐ Date (dd-Mon-yyyy):</li> <li>☐ Greater than 7 days</li> <li>☐ Less than 7 days</li> <li>☐ Unknown</li> <li>☑ Clinical Communication: Follow Fractured Hip Care Pathway</li> <li>☑ Clinical Communication: Request old charts</li> <li>☑ Clinical Communication: Verify if next of kin /agent /guardian is aware of the admission</li> </ul>
Diet and Nutrition
□ Regular Diet □ NPO: Starting now (may take sips of water for medication) □ NPO: Starting at midnight (may take sips of water for medication) □ Other diet orders
Patient Care
Activity ☑ Bedrest: Reposition every 2 hours
<ul> <li>Vital Signs</li> <li>☑ Vital Signs: respiratory rate (RR), pulse rate (P), blood pressure (BP), temperature (T), and oxygen saturation (SpO2) every 4 hours and PRN</li> <li>☑ Neurovascular Vital Signs: every 4 hours and PRN</li> </ul>
Patient Care Assessments  ☑ Level of Consciousness: assess every 4 hours and PRN

- ☑ Sedation Level Assessment/Monitoring: every 4 hours and PRN
- ☑ Pain Scale Monitoring: every 4 hours and PRN
- ☑ Confusion Assessment Method (CAM) every 8 hours and PRN if change in patient's clinical status. if CAM is positive, contact physician.

If CAM is positive, please see Delirium Investigation and Management Orders

☑ Pressure Injury/ Ulcer Prevention: Use pressure ulcer prevention strategies if Braden Score is 18 or less. See Provincial Clinical Knowledge Topic: Pressure Injury/ulcer Prevention, Adult -Inpatient Refer to local institutional practices until provincial orders available

Total to local modificational produced until provincial cracic available.				
Prescriber Name	Prescriber Signature	Date (dd-Mon-yyyy)	Time (hh mm)	

21170Bond (2020-07) Page 1 of 5



Last Name (Legal)		First Name (Legal)		
Preferred Name □ Last □ First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐Non-binary/Prefer not to disclos			se (X)	☐ Female ☐ Unknown

## Patient Care Continued

## Intake and Output

☐ Urinary Catheter – Insert: If unable to void, bladder scan and insert urinary catheter only as required (for volume greater than 300 mL). Attach urinary catheter to drainage bag.

☑ Intake and Output: every shift

### **Respiratory Care**

☑ O2 Therapy - Titrate to Saturation (Sp02): Titrate oxygen to maintain oxygen saturation (SpO2) greater than or equal to 92% or patient baseline

☑ Deep Breathing and Coughing: every 1 hour and PRN while awake

#### **Laboratory Investigations**

Perform all pre-selected investigations below unless already done prior to admission:

#### Hematology

- ☑ Complete Blood Count (CBC) with differential
- □ PT INR Choose for patients on oral or parenteral anticoagulant therapy. Consider for those with conditions associated with impaired coagulation (liver disease, malnutrition), history of excessive bleeding or family history of heritable coagulopathies.

#### Chemistry

- ☑ Alkaline Phosphatase
- ☑ Albumin
- ☑ Calcium (Ca)
- ☑ Carbon Dioxide (CO2)
- ☑ Chloride (CI)
- ☑ Creatinine
- ☑ Glucose Random
- ☑ Magnesium (Mg)
- ☑ Potassium (K)
- ☑ Sodium (Na)

Choose if not done in the past 3 months

☐ Vitamin B12

#### **Transfusion Medicine**

☑ Type and Screen

### **Diagnostic Investigations**

- ☐ Pelvis X-ray anterior-posterior (GR Pelvis, 1 Projection)
- ☐ Hip X-ray anterior-posterior (with 25 mm sphere) and lateral (GR Hip, 1 to 2 Projections)
  - ☐ Right Hip
  - ☐ Left Hip

If prior injury or surgery:

- ☐ Femur X-ray anterior-posterior and lateral (GR Femur, Unilateral)
  - ☐ Right femur
  - ☐ Left femur

Consider for patients with acute or chronic cardiopulmonary disease based on history and physical exam if it will change management:

☐ Chest X-ray anterior-posterior (GR Chest, 1 Projection)

#### **Other Tests**

☐ Electrocardiogram - 12 Lead

Prescriber Signature Date (dd-Mon-yyyy) Time (hh mm)

21170Bond (2020-07) Page 2 of 5



Last Name (Legal)		First Name (Legal)		
Preferred Name □ Last □ First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Female ☐ Non-binary/Prefer not to disclose (X) ☐ Unknown				

		□Non-binary/Prefer not to disclose	(X) ☐ Unknown		
IV Maintenance					
IV Maintenance  □ Intravenous Cannula – Insert: Initiate IV  Choose ONE: □ lactated ringers infusion IV at mL/hour □ sodium chloride 0.9% infusion IV at mL/hour □ dextrose 5% (D5W) – sodium chloride 0.9% infusion IV at mL/hour  Saline Lock					
☐ IV Peripheral Saline Flush/Lock: Saline lock IV					
VTE Prophylaxis To be reassessed daily if surgery delayed Choose ONE:					
For patients with a high risk of bleeding, use SCDs at least until the initial risk of bleeding decreases:  Sequential Compression Device; Apply, Continuous. For patients with a high risk of bleeding, use SCDs at least until the initial risk of bleeding decreases.		☐ AntiEmbolism stocking	յs; Apply, Continuous.		
□ heparin 5000 units SUBCUTANEOUSLY every 12 hours, hold dose on AM of surgery  For patients greater than 100 kg: □ heparin 5000 units SUBCUTANEOUSLY every 8 hours, hold dose on AM of surgery	OR	□ tinzaparin 2500 units severy 24 hours, hold do 12 hours prior to surge For patients greater than 100 tinzaparin dosing is 75 units/kg □ tinzaparin unit SUBCUTANEOUSLY dose minimum 12 hours	lose minimum ery kg: Recommended g is every 24 hours, hold		
If patient receiving Warfarin  ☐ Clinical Communication – Do Not Order/Give: warfarin, document date and time of last dose of warfarin taken. Time of last dose: Date (dd-Mon-yyyy) Time (hh:mm) ☐ phytonadione 5 mg PO once ☐ phytonadione 5 mg IV once ☐ PT INR, repeat in hour(s) post phytonadione					
If patient receiving Direct-Acting Oral Anticoagulant  ☐ Clinical Communication – Do Not Order/Give: dabigatran, rivaroxaban or apixaban, document date and time of last dose of dabigatran, rivaroxaban or apixaban taken. Heparin or LMWH not required for 48 hours while direct oral anticoagulant stopped.  Time of last dose: Date (dd-Mon-yyyy) Time (hh:mm)					
Prescriber Signature	Date	⊖ (dd-Mon-yyyy)	Time (hh mm)		

21170Bond (2020-07) Page 3 of 5



ne

## H

Last Name (Legal)		First Name (Legal)		
Preferred Name   Last   First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Non-binary/Prefer not to disc			se (X)	☐ Female ☐ Unknown

lip Fracture, Adult Pre-Op Order Set		
	Administrative Gender ☐ Male ☐ Non-binary/Prefer not to discle	
VTE Prophylaxis Continued		
Management of Anti-Platelet Therapy If patient has a mechanical valve consult cardiology or internal med and management	dicine regarding perioperative thromb	otic assessment
Continue clopidogrel for high risk vascular patients (within 12 mont.  ☐ clopidogrel 75 mg PO daily	hs of drug eluting stent, or 6 weeks or	f a bare metal stent)
For NON high risk vascular patient (have not had drug eluting stem Clinical Communication - Do Not Order/Give: clopidogrel taken. Time of last dose: Date (dd-Mo	opidogrel, document date and	time of last dose of
Continue aspirin if recent coronary artery stent ☐ aspirin 81 mg PO daily		
Hold aspirin (unless patient has had recent coronary artery stent)  □ Clinical Communication - Do Not Order/Give: as taken. Time of last dose: Date (dd-Mon-yyyy)	spirin, document date and time Time (hh:mm)	of last dose of aspirin
Medications		
Analgesics and Antipyretics  ☐ acetaminophen 650 mg PO/rectally QID. Maximum 30  High risk delirium prevention – reduce disruption of sleep at nigh		rom all sources.
Choose one (if applicable)  OR  □ HYDROmorphone 0.25 mg IV  □ morphine 2.5 mg IV/SUBCU	·	·
Antiemetics Avoid dimenhyDRINATE in the elderly		
Choose (if applicable)  □ ondansetron 4 mg PO/SL every 8	•	
Prescriber Signature Da	te (dd-Mon-yyyy)	Time (hh mm)

Page 4 of 5 21170Bond (2020-07)



Last Name (Legal)		First Name (Legal)		
Preferred Name □ Last □ First			DOB(dd-Mon-yyyy)	
PHN	ULI □ Same as PHN		s PHN	MRN
Administrative Gender ☐ Male ☐ Female ☐ Non-binary/Prefer not to disclose (X) ☐ Unknown				

	□Non-binary/Prefer not to disclose	(X) □ Unknown				
Medications Continued						
Antibiotic Prophylaxis Use <u>AHS Bugs and Drugs</u> for specific antibiotic recom Antibiotics should be given within 60 minutes of incision						
☐ ceFAZolin 2 g IV once, preoperative. Send dose to	operating room with patient.					
If ceFAZolin allergy or severe non-IgE mediated reaction	n to any β-lactam antibiotic:					
Choose one (if applicable)	nce, preoperative. Send dose to oper	ating room with				
250 mg increment (i.e., 500 r □ vancomycin mg	dosing is 15 mg/kg. Doses should be roundeding, 750 mg, 1000 mg, 1250 mg, 1500 mg, etc IV once, administer within 60 to 120 n or equal to 1 g over at least 60 minutes before	:.) ninutes				
1 g to 1.5 g over at least 90 m before incision.)	inutes before incision. Greater than 1.5 g over	120 minutes				
For patients with known MRSA colonization or active in	fection, Choose Both:					
Choose Both Choose Both	reoperative					
─────────────────────────────────────	mg IV once, administer within 6	0 to 120 minutes				
	or equal to 1 g over at least 60 minutes before nutes before incision. Greater than 1.5 g over					
Gastrointestinal Agents Order reflux acid reduction for patients with history of re	flux disorders					
(if applicable)	or Proton Pump inhibitors, specify home do not hold o	<i>medication:</i> lose preoperative.				
→ 〈 OR						
	ckers or Proton Pump inhibitors: once on admission <b>and then</b> once 2 l	hours preoperatively				
Consults/ Referrals						
If patient has abnormal PT INR, or if patient is on dabigatran, rivaroxaban or fondaparinux, consider Anesthesia, Internal Medicine, and/or Hematology consult.  □ Clinical Communication: No consults required □ MD Consult: Anesthesia						
□ MD Consult: Cardiology □ MD Consult: Internal Medicine						
LI MID Consuit. Internal Medicine						
Where consult service available:  ☐ MD Consult: Geriatric Medicine – to see within 72 hours of admission  ☐ MD Consult: Hematology  ☐ MD Consult: Acute Pain Service						
Prescriber Signature Date (dd-Mon-yyyy) Time (hh mm)						

21170Bond (2020-07) Page 5 of 5